The Vaxil-Hadassah collaboration, signed by Vaxil’s research and development (R&D) arm known as Vaxil BioTherapeutics Israel, intends to enhance R&D for the company’s immunotherapy platform including its lead product, Orphan Drug Designated Immucin.
The collaboration will include clinical samples obtained from cancer patients and healthy volunteers at Hadassah, which will be analysed in conjunction with Vaxil’s immune therapies and potential combination treatments currently under consideration.
In addition, top Hadassah scientist Professor Michael Shapira will be joining the Vaxil Scientific Advisory Board.
Prof. Dr. Shapira possesses in-depth knowledge of Vaxil’s immunotherapy, having led the company’s Phase-I/II clinical trial which demonstrated the safety of Immucin and established its potential to elicit a specific cellular and humoral response against MUC1-SP in a novel manner.
MUC1 is a highly prominent cancer target present on 90% of all human cancers yet has remained elusive in terms of optimal treatment protocol and target population. Vaxil believes its immunotherapy platform targets cancer antigens through a more effective path. Most promisingly, over 70% of the cancer patients who participated in Vaxil’s Phase-I/II exhibited a stable disease, including a majority of whom exhibited a durable response.
Furthermore, Vaxil announced the appointment of Gadi Levin as interim CEO and as a Director of the Board. Levin has a strong financial background combined with a successful track record in the biotech field. Previously, Levin was the Chief Financial Officer of Labstyle Innovations Ltd., a biotech focused on diabetes, and was subsequently appointed Chief Financial Officer of California-based immunotherapy company BriaCell Therapeutics.
Story by ProactiveInvestors